相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease
Christian Hoelscher
ALZHEIMERS & DEMENTIA (2014)
Identification and Characterization of GLP-1 Receptor-Expressing Cells Using a New Transgenic Mouse Model
Paul Richards et al.
DIABETES (2014)
A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs
D. Funch et al.
DIABETES OBESITY & METABOLISM (2014)
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies
S. Bonner-Weir et al.
DIABETES OBESITY & METABOLISM (2014)
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
J. Seufert et al.
DIABETES OBESITY & METABOLISM (2014)
Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials
Matteo Monami et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)
G. B. Bolli et al.
DIABETIC MEDICINE (2014)
Risk of pancreatitis in patients treated with incretin-based therapies
Juris J. Meier et al.
DIABETOLOGIA (2014)
GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
Charles Pyke et al.
ENDOCRINOLOGY (2014)
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
Kathleen M. Dungan et al.
LANCET (2014)
Pancreatic Safety of Incretin-Based Drugs - FDA and EMA Assessment
Amy G. Egan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies
Ling Li et al.
BMJ-BRITISH MEDICAL JOURNAL (2014)
Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study
Carlo B. Giorda et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects
Borje Darpo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Incretin Therapy and Islet Pathology: A Time for Caution
Steven E. Kahn
DIABETES (2013)
Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors
Alexandra E. Butler et al.
DIABETES (2013)
The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes The T-emerge 2 trial
Julio Rosenstock et al.
DIABETES CARE (2013)
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type2Diabetes Inadequately Controlled on Metformin A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
Julio Rosenstock et al.
DIABETES CARE (2013)
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Michael A. Nauck
DIABETES CARE (2013)
Do GLP-1-Based Therapies Increase Cancer Risk?
Michael A. Nauck et al.
DIABETES CARE (2013)
Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Bo Ahren et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)
Matthew C. Riddle et al.
DIABETES CARE (2013)
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
M. Pinget et al.
DIABETES OBESITY & METABOLISM (2013)
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
C. Kapitza et al.
DIABETES OBESITY & METABOLISM (2013)
Insulin- and glucagon-like peptide-1-induced changes in heart rate and vagosympathetic activity: why they matter
P. Valensi et al.
DIABETOLOGIA (2013)
Incretin-based therapies in the treatment of type 2 diabetes - More than meets the eye?
Krzysztof Labuzek et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2013)
GLP-1 agonists for type 2 diabetes: pharnnacokinetic and toxicological considerations
Maria J. Jespersen et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Thomas Forst et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
John B. Buse et al.
LANCET (2013)
Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals
M. Bomba et al.
CELL DEATH & DISEASE (2013)
Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction
Sheldon Russell
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2013)
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
Louise E. Robinson et al.
BMJ OPEN (2013)
Glucagonlike Peptide 1-Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus A Population-Based Matched Case-Control Study
Sonal Singh et al.
JAMA INTERNAL MEDICINE (2013)
A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice
Marc Evans et al.
DIABETES THERAPY (2013)
Exenatide Reduces Final Infarct Size in Patients With ST-Segment-Elevation Myocardial Infarction and Short-Duration of Ischemia
Jacob Lonborg et al.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2012)
Recent advances in incretin-based therapies
David Russell-Jones et al.
CLINICAL ENDOCRINOLOGY (2012)
The Human GLP-1 Analog Liraglutide and the Pancreas Evidence for the Absence of Structural Pancreatic Changes in Three Species
Niels C. B. Nyborg et al.
DIABETES (2012)
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) A 26-week double-blind study
David Russell-Jones et al.
DIABETES CARE (2012)
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)
Vivian A. Fonseca et al.
DIABETES CARE (2012)
Liraglutide: short-lived effect on gastric emptyingulong lasting effects on body weight
J. Jelsing et al.
DIABETES OBESITY & METABOLISM (2012)
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
D. Nathanson et al.
DIABETOLOGIA (2012)
Exenatide Extended-Release A Review of Its Use in Type 2 Diabetes Mellitus
Lesley J. Scott
DRUGS (2012)
GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation
Lars Wichmann Madsen et al.
ENDOCRINOLOGY (2012)
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Jacob Lonborg et al.
EUROPEAN HEART JOURNAL (2012)
Novel GLP-1 receptor agonists for diabetes
Alan J. Garber
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Belinda Gier et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Juris J. Meier
NATURE REVIEWS ENDOCRINOLOGY (2012)
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
Matteo Monami et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes
M. J. Davies et al.
DIABETES OBESITY & METABOLISM (2011)
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
C. Wysham et al.
DIABETIC MEDICINE (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
A thorough QT study to evaluate the effects of single-dose exenatide 10 μg on cardiac repolarization in healthy subjects
H. Linnebjerg et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
R. Pratley et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
The Safety of Incretin-Based Therapies-Review of the Scientific Evidence
Daniel J. Drucker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide
Laszlo Hegedus et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
Thomas Blevins et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Cardiovascular safety and diabetes drug development
Daniel J. Drucker et al.
LANCET (2011)
Incretin Receptors in Non-Neoplastic and Neoplastic Thyroid C Cells in Rodents and Humans: Relevance for Incretin-Based Diabetes Therapy
Beatrice Waser et al.
NEUROENDOCRINOLOGY (2011)
Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
Kristin Taylor et al.
BMC ENDOCRINE DISORDERS (2011)
The efficacy and safety of liraglutide
Kyeong-Hye Jeong et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2011)
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents
Krystyna Tatarkiewicz et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
Anne Gill et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
John B. Buse et al.
DIABETES CARE (2010)
DURATION-1 Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
John B. Buse et al.
DIABETES CARE (2010)
Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes
K. Kaku et al.
DIABETES OBESITY & METABOLISM (2010)
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
J. S. Nachnani et al.
DIABETOLOGIA (2010)
Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation
Lotte Bjerre Knudsen et al.
ENDOCRINOLOGY (2010)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
Michaela Diamant et al.
LANCET (2010)
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
Richard M. Bergenstal et al.
LANCET (2010)
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
Richard E. Pratley et al.
LANCET (2010)
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Shinichi Yachida et al.
NATURE (2010)
Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus
Yutaka Seino et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in Mice
Jacqueline A. Koehler et al.
DIABETES (2009)
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
Michael Nauck et al.
DIABETES CARE (2009)
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
Bernard Zinman et al.
DIABETES CARE (2009)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones et al.
DIABETOLOGIA (2009)
Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms
Elisabeth B. Ruettimann et al.
ENDOCRINOLOGY (2009)
Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes
Dhruba J. Chatterjee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Treatment of type 2 diabetes with incretin-based therapies
Sten Madsbad
LANCET (2009)
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
Alan Garber et al.
LANCET (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
The physiology of glucagon-like peptide 1
Jens Juul Holst
PHYSIOLOGICAL REVIEWS (2007)
Exenatide (Exendin-4)-induced pancreatitis - A case report
PS Denker et al.
DIABETES CARE (2006)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
分享论文
